Abstract
α-synuclein is a recently discovered protein that was first identified as the major non amyloid component of senile plaques, the cerebral lesion likely responsible for Alzheimers disease. The role of α-synuclein in another brain disease namely Parkinsons disease, has been more deeply documented. It appears that α-synuclein fills up the intracytoplasmic inclusions called Lewy bodies that likely contribute to the etiology of Parkinsons disease. Furthermore, rare familial forms of Parkinsons disease have been shown to be linked to autosomal dominant mutations of α-synucleins. Is α-synuclein a bridge between Alzheimers and Parkinsons diseases? Could it be seen as a common denominator for these two neurodegenerative diseases? These issues could be better addressed by further delineating the physiological function of α-synuclein and, as a corollary, the dysfunction taking place along with the diseases. Here, I will review the recent advances concerning the physiology of α-synuclein and will particularly focus on the post-traductional events leading to drastic biophysical transformations. I will describe recent works suggesting that these modifications directly modulate the normal function of α-synuclein, likely accounting for the dysfunction associated with Parkinsons disease and perhaps contributing to Alzheimers pathology.
Keywords: synuclein cell biology, synuclein, parkinson disease, lewy bodies
Current Molecular Medicine
Title: Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions
Volume: 3 Issue: 1
Author(s): C. Alves da Costa
Affiliation:
Keywords: synuclein cell biology, synuclein, parkinson disease, lewy bodies
Abstract: α-synuclein is a recently discovered protein that was first identified as the major non amyloid component of senile plaques, the cerebral lesion likely responsible for Alzheimers disease. The role of α-synuclein in another brain disease namely Parkinsons disease, has been more deeply documented. It appears that α-synuclein fills up the intracytoplasmic inclusions called Lewy bodies that likely contribute to the etiology of Parkinsons disease. Furthermore, rare familial forms of Parkinsons disease have been shown to be linked to autosomal dominant mutations of α-synucleins. Is α-synuclein a bridge between Alzheimers and Parkinsons diseases? Could it be seen as a common denominator for these two neurodegenerative diseases? These issues could be better addressed by further delineating the physiological function of α-synuclein and, as a corollary, the dysfunction taking place along with the diseases. Here, I will review the recent advances concerning the physiology of α-synuclein and will particularly focus on the post-traductional events leading to drastic biophysical transformations. I will describe recent works suggesting that these modifications directly modulate the normal function of α-synuclein, likely accounting for the dysfunction associated with Parkinsons disease and perhaps contributing to Alzheimers pathology.
Export Options
About this article
Cite this article as:
da Costa Alves C., Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions, Current Molecular Medicine 2003; 3 (1) . https://dx.doi.org/10.2174/1566524033361690
DOI https://dx.doi.org/10.2174/1566524033361690 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Diverse Network of Brain Histamine in Feeding: Dissect its Functions
in a Circuit-Specific Way
Current Neuropharmacology Interplay of G-proteins and Serotonin in the Neuroimmunoinflammatory Model of Chronic Stress and Depression: A Narrative Review
Current Pharmaceutical Design Breviscapine Combined with BMSCs Reduces Aβ Deposition in Rat with Alzheimer's Disease by Regulating Circular RNA ciRS-7
Current Molecular Medicine IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases
Current Pharmaceutical Design Anderson-Fabry Disease in Children
Current Pharmaceutical Design To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice
CNS & Neurological Disorders - Drug Targets Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons
Current Alzheimer Research Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Treatment of Lysosomal Storage Diseases: Recent Patents and Future Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Current Neuropharmacology A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Risk Factors for Suicide – An Alternative View
CNS & Neurological Disorders - Drug Targets Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer
Current Genomics